Natco Pharma Ltd has announced that the company has been in the forefront of bringing innovative therapies at affordable cost to improve the survival and quality of life of the cancer patients. Their latest introduction is the generic version of Lenalidomide, which is indicated for the treatment of Myelo Dysplastic Syndrome (MDS).

MDS is a type of neoplasm of the blood, which results in abnormally low amount of erythrocytes (red blood cells) and may be accompanied by low amount of thrombocytes (platelets) as well as neutrophils.

Currently, the treatment available for MDS is limited to supportive therapy like RBC transfusions, Erythropoietins and iron chelators. For the first time in India, the company is introducing Lenalidomide, which is seen as a targeted therapy in the treatment of MDS. Lenalidomide therapy may offer transfusion independence within 4 to 8 weeks, with the possibility of reversing cytogenetic abnormality as well. This therapy is recognized and well accepted all over the world by Haematologists and Medical Oncologists. a Natco press release said.

The company markets Lenalidomide under the brand name Lenalid, which is available as 5mg, 10mg, 15mg & 25mg capsules in 30's bottle pack. The company says a lot of compassionate consideration has gone in to pricing this product, which works out to be 95 per cent lesser than the international brand. Lenalid is available at the price 5mg - Rs 6000, 10mg - Rs 10800, 15mg - Rs 14500 & 25mg - Rs 22000.